Investigation of the Effect of NNC0194-0499 on Pharmacokinetics of a Combined Oral Contraceptive (Ethinylestradiol and Levonorgestrel) in Females of Non-childbearing Potential
Latest Information Update: 25 Feb 2025
Price :
$35 *
At a glance
- Drugs NNC0194 0499 (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 18 Feb 2025 Status changed from recruiting to completed.
- 05 Jan 2024 New trial record